ClinicalTrials.gg

Program

SPY002-072

A development code. Also written as “SPY072”.

Its studies are mostly in Hidradenitis Suppurativa · Arthritis, Rheumatoid, led by Spyre Therapeutics.

Furthest: phase 2, since Aug 21, 20253 company-led studies, 2 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Spyre Therapeutics32 open or runningphase 2since Aug 21, 2025Sep 30, 2024Oct 2027phase 2 · NCT07766005

Also a collaborator on its studies: altasciences-company-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 30, 2024First study: phase 1 study in HealthyFirst studyNCT06622070 · 40 enrolled · United States, Canada
  2. Aug 21, 2025Phase 2 study in Arthritis, RheumatoidNCT07148414 · 285 enrolled · United States, Bulgaria, Czechia and more
  3. Aug 10, 2026Phase 2 study in Hidradenitis SuppurativaNCT07766005 · 150 planned · United States, Canada

Ahead

  1. Oct 2027Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07766005

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07766005Hidradenitis Suppurativa · United States, Canada2RecruitingOct 2027150
NCT07148414Arthritis, Rheumatoid · United States, Bulgaria, Czechia and more2Active, not recruitingOct 31, 2026285
NCT06622070Healthy · United States, Canada1CompletedJul 28, 202640

How it is read

Names in the registry

  • “SPY002-072”, 2 entries
  • “SPY072”, 1 entry

Codes read as this program: SPY072, SPY002072.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.